ReNeuron Group Share Price (RENE)

2.20 +0.05 (+2.33%) delayed: 5:31PM BST
Bid price 2.10 Open price 2.15
Ask price 2.30 Prev close 2.20
High price 2.20 Spread 8.70%
Low price 2.13 Volume 979,025

Register now for FREE live ReNeuron Group share prices, ReNeuron Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get ReNeuron Group Level 2 Data, indepth research tools and investor commentary for ReNeuron Group (RENE) and other London Stock Exchange equities.

ReNeuron Group Share Price Chart

Advanced Charts >>

Register now for FREE ReNeuron Group share price charts

ReNeuron Group Share Price Information

Name ReNeuron Group Epic RENE
Sector Pharmaceuticals & Biotechnology ISIN GB00B0DZML60
Activites ReNeuron Group plc s a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered 'off-the-shelf' to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina. ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore. Index n/a

ReNeuron Group Key Numbers

Latest Share Price (p) 2.20 Net Gearing (%) -18.41
Market Capitalisation (£m) 68.04 Gross Gearing (%) 5.84
Shares in issue (m) 3,164.62 Debt Ratio 0.00
P/E Ratio -5.38 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.06
Dividend Yield (%) 0.00 Price to book value 1.01
Dividend cover (x) 0.00 ROCE (%) -18.99
Earning per share (p) -0.40 EPS Growth (%) 20.00
52 week high / low 3.70 / 2.03 DPS Growth (%) n/a

ReNeuron Group Director Deals

Dec.Date Type Director Pos No. of Shares
07/02/2017 BUY Michael Hunt FD 250,000
17/02/2016 EXR Michael Hunt FD 5,361,673
17/02/2016 SEXR Michael Hunt FD 5,111,673
03/02/2016 BUY John Berriman CH 318,476
30/01/2015 BUY Olav Hellebø CEO 322,778

More ReNeuron Group Director Deals >>

ReNeuron Group Company News

09:49 21/04/2017

ReNeuron updates on ophthalmology programmes

ReNeuron Group has reported very significant positive developments with its retinal disease programme. "The successful development of a cryopreserved formulation of our hRPC retinal cell therapy candidate enables an expansion of our clinical programmes in ophthalmology and also gives ReNeuron...

09:48 21/04/2017

ReNeuron updates on clinical strategy in stroke disability

ReNeuron Group says it expects to be able to begin a Phase III study with its CTX cell therapy candidate in stroke disability in H2 2017. "We look forward to reporting further progress over the months ahead," said CEO Olav Hellebo in a statement. "There are currently no therapeutic...

07:06 21/04/2017

FLASH: ReNeuron updates on ophthalmology programmes

Story provided by

More ReNeuron Group Company News >>

Register now for FREE ReNeuron Group company news

ReNeuron Group Share Price Discussions

2 months ago

RENEURON- stem cell technology (RENE)

Think this one could have the potetial to be really big... Check out the company info and post any thoughts you have... has massive potential

more than 1 year ago



Register now for FREE ReNeuron Group share price discussions